Critical Evaluation of Clinical Trials on Duraphat, Amine Fluoride, and Sodium Monofluorophosphate (SMFP)

INTRODUCTION

1. Duraphat - a 5% sodium fluoride (NaF) varnish (22,600 ppm F) in a colophonium/shellac resin base
2. Amine fluoride (AmF) - organic fluoride compounds (e.g., olaflur/dectaflur) used in dentifrices, gels, and mouthrinses
3. Sodium monofluorophosphate (SMFP/MFP) - an inorganic fluoride source widely used in toothpastes (typically at 1000-1450 ppm F)

PART I: DURAPHAT (5% SODIUM FLUORIDE VARNISH)

A. Recent Trials (2020-2026)

• Strengths: Multi-parameter outcome assessment (ICDAS-II + DIAGNOdent + photographic analysis), standardized application protocol, 12-month follow-up.
• Limitations: Small sample (n=66), single-center, no placebo arm (ethical constraints in high-risk population), reliance on a laser fluorescence device which has variable reliability for remineralization assessment. The intensive application protocol (quarterly) may not reflect routine clinical practice.
• Significance: Confirms Duraphat's remineralizing capability but suggests newer biomimetic agents (CRFP) may outperform it in WSL management. However, CRFP contains P11-4 (self-assembling peptide) making this a compound comparison rather than a pure fluoride comparison.

• Strengths: Largest three-arm fluoride varnish RCT in ECC prevention (n=582); double-blind design; computer-generated randomization; adequate follow-up; standardized application frequency.
• Limitations: High caries incidence in all groups (>59%) questions whether 3-monthly application is sufficient in very high-risk children. No untreated control group (ethical), making absolute effect size impossible to determine. Generalizability may be limited by the specific high-risk Hong Kong population studied.
• Significance: Demonstrates that adding calcium-phosphate compounds to Duraphat does not confer additional caries-preventive benefit in high-risk preschoolers; Duraphat alone has equivalent efficacy to more expensive formulations. This challenges the rationale for premium-priced varnish products.

• Strengths: NMA allows indirect comparisons between agents never directly compared; GRADE-CINeMA framework for evidence certainty; broad database search.
• Limitations: Majority of included studies were high-risk of bias; significant heterogeneity in outcome reporting; 5% NaF varnish was assessed as a class, not Duraphat specifically. Evidence certainty rated "very low to moderate" for most interventions.
• Significance: Provides the highest level of evidence that 5% NaF varnish (Duraphat prototype) is one of only two professionally applied topical fluorides with sufficient evidence for ECC prevention.

• Strengths: GRADE approach; mixed professional and self-applied interventions compared; only NMA on root caries prevention.
• Limitations: Limited number of trials (9); only two studies included 5% NaF varnish specifically; moderate-to-high risk of bias in included studies. Root caries outcomes are difficult to standardize.
• Significance: Validates Duraphat (5% NaF varnish) as a professionally applied agent with meaningful root caries prevention, though annual SDF surpasses it in this specific indication.

• Strengths: First systematic review exclusively in older adults; distinguishes caries prevention from arrest; low risk-of-bias studies included.
• Limitations: Only 7 studies; limited data exclusively for Duraphat (results often pooled with other 5% NaF products); not all studies were placebo-controlled.
• Significance: Establishes that Duraphat-class NaF varnish is the most clinically accessible professionally applied agent for root caries prevention in the elderly, where root caries prevalence is high.

B. Older Landmark Duraphat Trials (1975-2012)

• Limitations: No blinding; small sample; 1-year follow-up is insufficient for mature trial conclusions. Outcome measurement based on WHO DMFS criteria without radiographic adjunct.
• Significance: The foundational trial establishing that twice-yearly Duraphat application was clinically viable, forming the basis for all subsequent dosing recommendations.

• Limitations: Non-randomized design; concurrent water fluoridation variability; no blinding.
• Significance: Extended Duraphat evidence from schoolchildren to preschoolers, a more vulnerable demographic.

• Significance: One of the first studies from an unfluoridated community showing Duraphat's independent caries preventive efficacy, supporting its use in non-fluoridated regions.

• Strengths: Radiographic assessment; 3-year follow-up; adolescent population with high proximal caries risk.
• Limitations: No explicit randomization description; Sweden's high background fluoride exposure.
• Significance: Demonstrated that Duraphat has specific benefit for approximal surfaces, which are the most caries-prone in adolescents.

• Significance: Established the dose-response relationship for Duraphat application frequency, supporting 2-4 applications/year as standard practice.

PART II: AMINE FLUORIDE (AmF)

• Strengths: Randomized design; objective photographic quantification using ImageJ software; clinically important patient population (orthodontic patients with high WSL risk).
• Limitations: Small sample (n=50, 25 per group); single-centre; only 6-month follow-up; no blinding of outcome assessors; reliance on photograph analysis introduces inter-observer variability despite software use. The control used fluoridated toothpaste, which is itself an active treatment, making this a "head-to-head" rather than a "vs. no treatment" trial.
• Significance: Provides contemporary evidence that AmF mouthwash offers incremental benefit over fluoride toothpaste alone in preventing demineralization during orthodontic treatment - a population where caries risk is significantly elevated.

• Strengths: Bioavailability data are clinically meaningful as they explain mechanism of superiority.
• Limitations: Surrogate outcomes (fluoride concentration rather than caries incidence); laboratory-clinical hybrid design; small n.
• Significance: Provides mechanistic evidence underpinning why AmF clinical trials show better performance than simple NaF comparisons might predict.

• Strengths: 2-year follow-up; periodontal maintenance population (high ecological validity for periodontally vulnerable patients); standardized product use; multi-centre supportive care setting.
• Limitations: Underpowered for root caries outcome detection (n=80 for a relatively rare event); frequent supportive periodontal therapy in both groups may have confounded results by reducing bacterial load independently of fluoride; high drop-out potential due to periodontal treatment complexity. The trend favored AmF/SnF2 but statistical power was insufficient.
• Significance: One of the few long-term RCTs examining root caries specifically in periodontally compromised patients. Results are inconclusive but suggest a trend favoring AmF/SnF2. The failure to reach significance is likely a Type II error given sample size constraints.

• Strengths: Well-controlled in situ design with standardized acid challenges; separates erosion from caries - valuable for erosion management.
• Limitations: In situ models may not fully replicate in vivo erosion dynamics; short (4-week) observation period; gel formulation not directly translatable to standard toothbrushing use.
• Significance: Established AmF/SnF2 as the superior fluoride formulation for tooth erosion prevention, a distinct clinical benefit beyond caries prevention.

• Limitations: Consensus statements carry inherent potential for expert bias; based on trials of varying quality.
• Significance: Represented the first authoritative synthesis declaring AmF as a validated alternative to NaF in caries prevention dentifrices.

• SMFP dentifrice: DMFT reduction 7.02%, DMFS reduction 5.17%, df rate reduction 25.26%
• AmF dentifrice: DMFT reduction 21.62%, DMFS reduction 20.94%, df rate reduction 48.66%
• AmF produced approximately 3x greater caries reduction than SMFP relative to non-fluoride control.

• Strengths: Large sample (n=2,008); double-blind; randomized; 3-year follow-up; head-to-head comparison with SMFP; non-fluoride control group (permissible in 1982 pre-Strasbourg era); "unsupervised" use reflects real-world conditions.
• Limitations: Unsupervised use means variable compliance is uncontrolled; France was not fluoridated, ensuring no background fluoridation confound; both dentifrices were at lower-than-modern concentrations (typically 500-800 ppm in 1982 formulations); the marked superiority of AmF may partly reflect the particularly low SMFP concentration in that era's formulations.
• Significance: The most often cited head-to-head comparison between AmF and SMFP in a clinical setting. Demonstrated clinically and statistically significantly superior caries prevention with AmF. This trial had major influence on European dentifrice formulation strategy, particularly in Switzerland and Germany.

• Limitations: Pre-modern trial design; limited details on randomization and blinding; shorter follow-up.
• Significance: One of the first RCTs on AmF gel, establishing it as a viable professional topical fluoride alternative.

PART III: SODIUM MONOFLUOROPHOSPHATE (SMFP/MFP)

• Strengths: Triple-blind design; large sample (n=610); both primary and permanent dentitions assessed; ICDAS-II scoring (detects initial lesions); adequate follow-up; 4-arm design allowing dose comparison; closely supervised brushing.
• Limitations: Supervised brushing (3x/day) is not representative of unsupervised home use; the Italian population may have different dietary and fluoride exposure patterns from other settings; HAF vs. SMFP is not a traditional comparison - SMFP served as the active comparator, not as the primary agent being tested; children aged 4-7 may represent a demographic where primary tooth caries dynamics differ substantially from permanent teeth.
• Significance: Demonstrates that SMFP toothpastes at both 1000 and 1450 ppm, while providing caries reduction vs. no fluoride (by historical reference), are outperformed by biomimetic hydroxyapatite-fluoride formulations. Raises questions about whether SMFP should remain the benchmark comparator in future trials. Importantly, confirms the dose effect (1450 > 1000 ppm) for SMFP.

• Significance: Mechanistically important - confirms that SMFP's already indirect fluoride bioavailability is further compromised by post-brush rinsing. Supports clinical instruction for patients to spit but not rinse after brushing SMFP toothpastes.

• SMFP dentifrice produced a statistically significant but clinically modest 7% DMFT reduction in the Strasbourg trial. This represented meaningful caries prevention relative to no fluoride, but substantially less than AmF.

PART IV: COMPARATIVE CRITICAL ANALYSIS

PART V: OVERALL CRITICAL APPRAISAL OF THE EVIDENCE BASE

CONCLUSION

1. Duraphat has the strongest and most current evidence base for professional fluoride application. It remains the gold-standard professionally applied topical fluoride, effective for coronal and root caries prevention across all age groups, though emerging agents (SDF, CRFP) may challenge its primacy in specific indications.
2. Amine fluoride demonstrates superior bioavailability, plaque penetration, and erosion protection vs. NaF/SMFP. Its evidence base for caries prevention in dentifrices is strong from mid-20th century European trials but requires contemporary large-scale validation. Its combination with stannous fluoride (AmF/SnF2) provides the best evidence for chemoprophylaxis in erosion and periodontal populations.
3. SMFP remains a safe, effective, and widely used caries-preventive dentifrice agent, but its evidence base is aging, its mechanism is less efficient than direct fluoride sources, and it is now being outperformed in head-to-head trials by both AmF and biomimetic HAF formulations. Future research should focus on modern comparative trials for SMFP against contemporary formulations.

REFERENCES

1. Khairy SM, Talaat DM, Dowidar KML. Remineralization of white spot lesions in primary teeth using intensive application of Curodont Repair Fluoride Plus, MI Varnish, or Duraphat varnish (RCT). J Evid Based Dent Pract. 2025;Sep:102163. [PMID: 40716822]
2. Manchanda S, Liu P, Sardana D, et al. Randomized clinical trial to compare three fluoride varnishes in preventing early childhood caries. J Dent. 2024;147:105141. [PMID: 38901821]
3. Chan AKY, Tamrakar M, Jiang CM, et al. Clinical evidence for professionally applied fluoride therapy to prevent and arrest dental caries in older adults: A systematic review. J Dent. 2022;125:104273. [PMID: 36058347]
4. Cagetti MG, Cocco F, Wierichs RJ, et al. Efficacy of HAF toothpastes in primary and permanent dentitions: A 2-years triple-blind RCT. J Dent. 2022;121:104049. [PMID: 35139410]
5. Manchanda S, Sardana D, Liu P, et al. Topical fluoride to prevent early childhood caries: Systematic review with network meta-analysis. J Dent. 2022;117:103885. [PMID: 34780874]
6. Zhang J, Sardana D, Li KY, et al. Topical fluoride to prevent root caries: Systematic review with network meta-analysis. J Dent Res. 2020;99(5):495-502. [PMID: 32142400]
7. Ravi Kiran KR, Sabrish S, Mathew S, et al. Effectiveness of amine fluoride mouthwash in preventing white spot lesions during fixed orthodontic therapy - A randomized control trial. Indian J Dent Res. 2023;34(3):234-238. [PMID: 38197343]
8. Naumova EA, Kuehnl P, Hertenstein P, et al. Fluoride bioavailability in saliva and plaque. BMC Oral Health. 2012;12:3. [PMID: 22230722]
9. Paraskevas S, Danser MM, Timmerman MF, et al. Amine fluoride/stannous fluoride and incidence of root caries in periodontal maintenance patients: A 2-year evaluation. J Clin Periodontol. 2004;31(11):965-971. [PMID: 15491311]
10. Ganss C, Klimek J, Brune V, et al. Effects of two fluoridation measures on erosion progression in human enamel and dentine in situ. Caries Res. 2004;38(6):561-566. [PMID: 15528912]
11. Einwag J, Hellwig E, Hotz P, et al. The relative caries-inhibiting efficacy of amine fluoride and sodium fluoride in compatible dentifrices: Results of a consensus conference. Quintessence Int. 1995;26(10):657-663. [PMID: 8935113]
12. Cahen PM, Frank RM, Turlot JC, Jung MT. Comparative unsupervised clinical trial on caries inhibition effect of monofluorophosphate and amine fluoride dentifrices after 3 years in Strasbourg, France. Community Dent Oral Epidemiol. 1982;10(5):238-241. [PMID: 6754242]
13. Shern RJ, Duany LF, Senning RS. Clinical study of an amine fluoride gel and acidulated phosphate fluoride gel. Community Dent Oral Epidemiol. 1976;4(4):138-143. [PMID: 782777]
14. Koch G, Petersson LG. Caries preventive effect of a fluoride-containing varnish (Duraphat) after 1 year's study. Community Dent Oral Epidemiol. 1975;3(6):262-266. [PMID: 1059514]
15. Holm AK. Effect of fluoride varnish (Duraphat) in preschool children. Community Dent Oral Epidemiol. 1979;7(5):241-245. [PMID: 295702]
16. Grodzka K, Augustyniak L, Budny J, et al. Caries increment in primary teeth after application of Duraphat fluoride varnish. Community Dent Oral Epidemiol. 1982;10(2):55-59. [PMID: 6952970]
17. Modeer T, Twetman S, Bergstrand F. Three-year study of the effect of fluoride varnish (Duraphat) on proximal caries progression in teenagers. Scand J Dent Res. 1984;92(5):400-407. [PMID: 6593805]
18. Petersson LG, Arthursson L, Ostberg C, et al. Caries-inhibiting effects of different modes of Duraphat varnish reapplication: A 3-year radiographic study. Caries Res. 1991;25(1):70-73.
19. Marinho VCC, Worthington HV, Walsh T, et al. Fluoride varnishes for preventing dental caries in children and adolescents. Cochrane Database Syst Rev. 2013;(7):CD002279.

Answer Structure Summary

Part I - Duraphat (5% NaF Varnish): 10 trials evaluated

• 2025: Khairy et al. - RCT comparing Duraphat vs CRFP vs MI Varnish for WSL remineralization (PMID 40716822) - CRFP superior, but Duraphat still effective
• 2024: Manchanda et al. - Large RCT (n=582) showing Duraphat equivalent to calcium-phosphate-enhanced varnishes in ECC prevention (PMID 38901821)
• 2022: Two systematic reviews/NMAs establishing Duraphat-class varnish as evidence-based for ECC and root caries prevention (PMIDs 34780874, 32142400, 36058347)
• 1975-1991: Landmark trials by Koch & Petersson, Holm, Grodzka, Modeer, Petersson establishing the dosing, safety, and efficacy foundations

Part II - Amine Fluoride: 7 trials evaluated

• 2023: Ravi Kiran et al. - RCT showing AmF mouthwash prevents WSLs during orthodontics (PMID 38197343)
• 2012: Naumova et al. - Mechanistic data showing superior plaque fluoride retention with AmF (PMID 22230722)
• 2004: Paraskevas et al. - 2-year RCT for root caries in periodontal patients - trend favoring AmF/SnF2 but underpowered (PMID 15491311)
• 2004: Ganss et al. - AmF/SnF2 superior for erosion prevention (PMID 15528912)
• 1982: Cahen et al. - The critical head-to-head AmF vs SMFP trial showing AmF produced 3x greater caries reduction (PMID 6754242)

Part III - SMFP: Historical overview + critical comparison

• 2022: Cagetti et al. - SMFP vs HAF toothpastes; HAF outperformed SMFP (PMID 35139410)
• Historical Torell, Volpe-era trials establishing SMFP efficacy vs. placebo

Part IV - Comparative Table (Duraphat vs AmF vs SMFP)

Part V - Overall Evidence Appraisal with strengths/limitations for each agent